DaVita Responds to HHS Kidney Care National Plan, Emphasizing Early Detection, Innovation and Patient Choice
DaVita, a leading provider of kidney care services in the United States, has responded to the U.S. Department of Health and Human Services’ (HHS) Kidney Care National Plan, reaffirming its commitment to improving kidney health through early disease detection, treatment innovation, expanded patient access and greater coordination across the health care system. The company has expressed support for the administration’s efforts to accelerate progress for Americans living with kidney disease while emphasizing the importance of building on existing advancements in clinical care and treatment delivery.
In its statement, DaVita said the introduction of the national plan reflects several of its longstanding priorities, including identifying kidney disease earlier, slowing disease progression, expanding treatment choices and improving coordination throughout the kidney care continuum. The company also highlighted its ongoing work with federal leaders, investments in technology and clinical innovation, and efforts to help patients access kidney transplantation.
The announcement comes as kidney disease remains a significant health care challenge in the United States. Many people with chronic kidney disease (CKD) are unaware of their condition, which can delay diagnosis and opportunities for intervention. DaVita cited an estimate that 87% of adults with chronic kidney disease do not know they have it, underscoring the need for improved screening, awareness and timely treatment.
The company said it shares the administration’s urgency in addressing kidney disease and intends to continue working with government leaders to turn the national plan’s objectives into meaningful improvements for patients.
At the same time, DaVita emphasized that the kidney care sector has already made substantial progress in innovation and that large-scale health care organizations can play an important role in bringing new technologies and treatment approaches to patients.
DaVita Supports Earlier Detection and Better Kidney Disease Management
Early detection is a central priority in efforts to improve kidney health. Chronic kidney disease can develop over time, and patients may not experience noticeable symptoms during its earlier stages. Without appropriate screening and medical evaluation, the condition can remain undiagnosed until kidney function has deteriorated significantly.
DaVita’s response to the HHS plan emphasizes the importance of identifying kidney disease earlier so patients and clinicians can take steps to manage the condition and potentially slow its progression.
Early identification can help health care professionals assess kidney function, monitor changes over time and determine whether interventions are appropriate. Depending on the patient’s condition, management may include medication, lifestyle changes, treatment of related conditions and regular monitoring by health care professionals.
Improved coordination among primary care providers, kidney specialists and other clinicians can also help patients receive appropriate care as their needs change. Patients with chronic kidney disease may require support from multiple specialties, particularly when they have other health conditions that affect kidney function or overall health.
DaVita said the national plan’s focus on earlier diagnosis, disease management and patient choice aligns with priorities the company has pursued for years.
The company also highlighted its efforts to expand multispecialty capabilities. By connecting kidney care with additional clinical expertise, DaVita aims to help more patients benefit from treatment advances that may slow disease progression.
These efforts are intended to support patients at different stages of kidney disease rather than focusing exclusively on dialysis after kidney function has declined substantially.
The broader objective is to strengthen the continuum of care, allowing patients to receive appropriate support as their condition develops. Better coordination may also help clinicians identify changes in a patient’s health and adjust treatment plans according to individual needs.
Value-Based Care Models Aim to Improve Patient Outcomes
DaVita pointed to value-based kidney care as another important element in efforts to improve treatment and patient outcomes.
Traditional health care payment arrangements may emphasize the delivery of individual services. Value-based care models, by contrast, seek to connect reimbursement and care delivery with measures of quality, outcomes and the effective management of a patient’s health.
In kidney care, these approaches can encourage earlier intervention, coordinated treatment and attention to the patient’s overall health rather than concentrating exclusively on individual dialysis sessions.
DaVita said a majority of its patients are now supported by care plans that extend beyond dialysis, reflecting what it described as decades of advocacy and innovation in care delivery.
The company also highlighted the Kidney Care Choices model developed through the Centers for Medicare & Medicaid Services Innovation Center (CMMI). The model is designed to encourage coordinated, value-based care for patients with chronic kidney disease and end-stage kidney disease.
DaVita said the model has demonstrated the potential for value-based kidney care to make a meaningful difference in patients’ lives.
The approach reflects a broader shift toward managing kidney disease across its progression, including efforts to identify patients earlier, coordinate treatment and help eligible patients consider options such as transplantation.
For patients, a more coordinated care model can provide opportunities for clinicians to address different aspects of kidney health in a connected manner. It can also support discussions about treatment preferences, disease management and potential future care needs.
However, the effectiveness of any care model depends on factors such as patient circumstances, clinical practices, access to services and the ability of participating organizations to coordinate treatment effectively.
DaVita’s response positions value-based care as one component of a wider strategy to improve kidney health and make advances in treatment more accessible.
Technology and Clinical Innovation Remain Central to Kidney Care
While DaVita welcomed many of the priorities outlined in the HHS plan, the company challenged the suggestion that kidney care has lacked innovation or that organizational scale necessarily limits progress.
The company said kidney care is increasingly an area where technology, clinical science and new approaches to chronic disease management are being developed and applied.
DaVita has invested in proprietary technology intended to connect care across different settings and support more personalized treatment. According to the company, these investments are designed to help clinicians coordinate care more effectively and respond to patients’ individual needs.
Technology can support kidney care in several ways, including facilitating communication, helping clinicians access relevant patient information and supporting the management of complex treatment plans.
For patients who receive care from multiple providers, coordination across settings is particularly important. Information about kidney function, medications, related conditions and treatment history can influence clinical decisions and the timing of interventions.
Digital tools and connected care systems may help providers organize this information and improve communication, although their benefits depend on implementation, usability and the quality of the information available.
DaVita also reported that it is rapidly deploying a major clinical innovation across its centers. The company said this development brings dialysis treatment one step closer to the natural kidney and is associated with meaningful improvements in clinical outcomes and quality of life.
The statement did not identify the technology by name or provide detailed clinical data describing the reported outcomes. Consequently, the specific treatment mechanisms and the extent of the improvements cannot be independently assessed from the announcement alone.
Nevertheless, the company’s emphasis on this initiative illustrates its position that innovation is already taking place within the kidney care sector.
DaVita argued that its scale helps support investments in specialized expertise, technology and clinical development. It also said scale can enable advancements to reach patients more quickly and broadly.
This perspective contrasts with the suggestion that large organizations may hinder innovation. DaVita’s position is that organizational reach can help translate investments into practical improvements across multiple care settings.
Kidney Transplant Access Remains a Major Challenge
Kidney transplantation is another key area highlighted in DaVita’s response to the national plan.
For eligible patients with advanced kidney disease, transplantation may offer an alternative to long-term dialysis. However, access depends on numerous factors, including medical eligibility, evaluation, organ availability and the ability to navigate the transplant process.
DaVita said it helps patients navigate transplantation, invests in technology intended to connect patients with transplant centers and pursues innovations designed to address the shortage of available organs.
The company cited an estimated 90,000 Americans who remain on the kidney transplant waiting list, highlighting the scale of the challenge facing patients who may benefit from transplantation.
The shortage of viable donor organs remains a major constraint on transplant access. Even when patients are medically eligible and willing to undergo transplantation, an appropriate organ may not be available when needed.
Improving transplant access therefore requires efforts across several areas, including patient education, evaluation processes, coordination between dialysis providers and transplant centers, and measures that increase the availability of suitable organs.
DaVita’s focus on connecting patients and transplant centers reflects the importance of helping eligible patients understand and navigate the steps involved in transplant evaluation.
Technology may also help improve communication and information sharing between patients and clinical teams. Better coordination can support the management of evaluation requirements and help patients understand the next steps in the process.
However, digital tools alone cannot resolve the underlying shortage of donor organs. Expanding access requires broader clinical, operational and policy efforts, alongside continued attention to transplant safety and eligibility.
DaVita acknowledged that progress has not occurred quickly enough, pointing to the critical shortage of viable human organs as a central obstacle.
The company’s response supports continued innovation in transplantation while recognizing that meaningful improvements will require cooperation among health care providers, transplant centers, policymakers and other stakeholders.
Distinguishing Disease Prevention From Kidney Failure Treatment
DaVita emphasized that efforts to prevent kidney disease and slow its progression must be considered alongside the need to provide high-quality treatment to people who have already developed kidney failure.
The company said both objectives are essential to improving kidney health in the United States.
Preventing kidney disease or slowing its progression can help some patients delay the need for advanced treatment. However, not all cases can be prevented, and some patients will continue to progress to kidney failure despite appropriate medical management.
For people whose kidneys can no longer adequately perform their essential functions, dialysis and transplantation can be lifesaving treatment options.
Dialysis helps remove waste products and excess fluid from the blood when kidney function is severely impaired. Depending on the patient’s circumstances, dialysis may be provided through different treatment approaches, with care plans tailored to clinical needs and individual preferences.
Transplantation can provide another treatment option for eligible patients, but it is not immediately available or suitable for everyone.
DaVita’s statement argues that health care policy must recognize these distinct needs. Preventive strategies and treatments intended to slow disease progression should not be treated as substitutes for maintaining reliable, high-quality services for patients who already require dialysis or other advanced kidney care.
This distinction is important when evaluating national kidney health initiatives because the patient population includes people at different stages of disease. Some may benefit from earlier detection and interventions, while others require ongoing treatment to manage advanced kidney failure.
A comprehensive approach must therefore support both prevention and treatment, ensuring that advances in early disease management do not diminish attention to patients who depend on established kidney care services.
Partnership With Federal Leaders to Advance Kidney Health
DaVita said it has worked with federal leaders for decades and looks forward to continuing that partnership as the Kidney Care National Plan moves forward.
The company expressed support for the administration’s urgency while emphasizing the importance of building on existing programs, identifying areas where progress is needed and accelerating the adoption of effective approaches.
The national plan creates an opportunity for stakeholders across the kidney care system to examine how screening, care coordination, treatment options and transplantation services can be improved.
Achieving meaningful progress will require collaboration among policymakers, providers, researchers, technology developers and organizations involved in kidney disease management.
For DaVita, its response combines support for the plan’s broad objectives with a call to recognize the existing contributions of care providers and ongoing innovations in the sector.
The company said there is broad agreement on the goal of changing the trajectory of kidney disease. It also emphasized that efforts to improve outcomes must address the needs of patients across the full continuum of care.
Improving Access, Innovation and Patient Choice
DaVita’s response to the HHS Kidney Care National Plan reinforces its stated commitment to early detection, coordinated treatment, technology development and expanded patient choice.
The company highlighted its work in value-based care, multispecialty services, transplant navigation and clinical innovation as examples of efforts intended to improve kidney care.
At the same time, DaVita stressed that the prevention of kidney disease and the treatment of established kidney failure are complementary priorities. Both require sustained attention if the United States is to improve outcomes for people affected by kidney disease.
The company also maintained that scale can support innovation by enabling investments in expertise and technology and helping make new approaches available to patients across a wider network of care settings.
As the administration advances its national kidney care agenda, DaVita said it is prepared to work with federal leaders to translate the plan’s ambitions into practical improvements for patients.
The broader challenge will be to ensure that earlier diagnosis, effective disease management, transplantation access and high-quality dialysis care advance together. For the thousands of patients living with kidney disease and those awaiting transplantation, progress will depend on sustained collaboration and solutions that address both long-term prevention and immediate treatment needs.
Through continued partnership, clinical innovation and attention to patient choice, DaVita says it intends to contribute to efforts to improve kidney health and strengthen care for Americans living with kidney disease.
Source link: https://newsroom.davita.com/
